


World Journal of *Transplantation*

Quarterly Volume 14 Number 3 September 18, 2024



EDITORIAL

Gonzalez FM, Gonzalez Cohens FDR. Kidney transplantation outcomes: Is it possible to improve when good results are falling down? *World J Transplant* 2024; 14(3): 91214 [DOI: [10.5500/wjt.v14.i3.91214](https://doi.org/10.5500/wjt.v14.i3.91214)]

Gonzalez Cohens F, Gonzalez FM. Donor hepatectomy time and liver transplantation outcomes: An opportunity that cannot be dismissed. *World J Transplant* 2024; 14(3): 92859 [DOI: [10.5500/wjt.v14.i3.92859](https://doi.org/10.5500/wjt.v14.i3.92859)]

MINIREVIEWS

Nazir A. Exercise as a modality to improve heart transplantation-related functional impairments: An article review. *World J Transplant* 2024; 14(3): 91637 [DOI: [10.5500/wjt.v14.i3.91637](https://doi.org/10.5500/wjt.v14.i3.91637)]

Spring AM, Gjelaj C, Madan S, Patel SR, Saeed O, Murthy S, Rochlani Y, Sims DB, Vukelic S, Forest SJ, Borgi JF, Goldstein DJ, Jorde UP. Evolution of heart transplant donor characteristics in the 21st century: A United States single center's experience. *World J Transplant* 2024; 14(3): 92721 [DOI: [10.5500/wjt.v14.i3.92721](https://doi.org/10.5500/wjt.v14.i3.92721)]

Yilmaz ZB, Memisoglu F, Akbulut S. Management of cytomegalovirus infection after liver transplantation. *World J Transplant* 2024; 14(3): 93209 [DOI: [10.5500/wjt.v14.i3.93209](https://doi.org/10.5500/wjt.v14.i3.93209)]

Aboghanem A, Prasad GVR. Disorders of potassium homeostasis after kidney transplantation. *World J Transplant* 2024; 14(3): 95905 [DOI: [10.5500/wjt.v14.i3.95905](https://doi.org/10.5500/wjt.v14.i3.95905)]

Sesa V, Silovski H, Basic-Jukic N, Kosuta I, Sremac M, Mrzljak A. Genitourinary tumors and liver transplantation: A comprehensive review. *World J Transplant* 2024; 14(3): 95987 [DOI: [10.5500/wjt.v14.i3.95987](https://doi.org/10.5500/wjt.v14.i3.95987)]

Prasad P, Sharma S, Mohanasundaram S, Agarwal A, Verma H. Tuberculosis in kidney transplant candidates and recipients. *World J Transplant* 2024; 14(3): 96225 [DOI: [10.5500/wjt.v14.i3.96225](https://doi.org/10.5500/wjt.v14.i3.96225)]

Badwei N. Challenges related to clinical decision-making in hepatocellular carcinoma recurrence post-liver transplantation: Is there a hope? *World J Transplant* 2024; 14(3): 96637 [DOI: [10.5500/wjt.v14.i3.96637](https://doi.org/10.5500/wjt.v14.i3.96637)]

ORIGINAL ARTICLE**Retrospective Cohort Study**

Boateng S, Ameyaw P, Gyabaah S, Adjepong Y, Njei B. Recipient functional status impacts on short and long-term intestinal transplant outcomes in United States adults. *World J Transplant* 2024; 14(3): 93561 [DOI: [10.5500/wjt.v14.i3.93561](https://doi.org/10.5500/wjt.v14.i3.93561)]

Verdiales C, Baxter L, Lim HJ, Beck G, Moser MA. Matched pair analysis of the effect of longer hypothermic machine perfusion time on kidney transplant outcomes. *World J Transplant* 2024; 14(3): 95233 [DOI: [10.5500/wjt.v14.i3.95233](https://doi.org/10.5500/wjt.v14.i3.95233)]

Retrospective Study

Georgopoulou GA, Papisotiriou M, Ntrinias T, Savvidaki E, Goumenos DS, Papachristou E. Impact of bisphosphonate treatment on bone mineral density after kidney transplant. *World J Transplant* 2024; 14(3): 92335 [DOI: [10.5500/wjt.v14.i3.92335](https://doi.org/10.5500/wjt.v14.i3.92335)]

Kwon H, Sandhu Z, Sarwar Z, Andacoglu OM. Impact of Medicaid expansion on kidney transplantation in the State Oklahoma. *World J Transplant* 2024; 14(3): 92981 [DOI: [10.5500/wjt.v14.i3.92981](https://doi.org/10.5500/wjt.v14.i3.92981)]

Chung W, Wong K, Ravindranayagam N, Tang L, Grace J, Wong D, Con D, Sinclair M, Majumdar A, Kutaiba N, Hui S, Gow P, Muralidharan V, Dobrovic A, Testro A. Statin, aspirin and metformin use and risk of hepatocellular carcinoma related outcomes following liver transplantation: A retrospective study. *World J Transplant* 2024; 14(3): 94914 [DOI: [10.5500/wjt.v14.i3.94914](https://doi.org/10.5500/wjt.v14.i3.94914)]

Alnagar A, Zakeri N, Koilias K, Faulkes RE, Brown R, Cain O, Perera MTPR, Roberts KJ, Sanabria-Mateos R, Bartlett DC, Ma YT, Sivakumar S, Shetty S, Shah T, Dasari BVM. SIMAP500: A novel risk score to identify recipients at higher risk of hepatocellular carcinoma recurrence following liver transplantation. *World J Transplant* 2024; 14(3): 95849 [DOI: [10.5500/wjt.v14.i3.95849](https://doi.org/10.5500/wjt.v14.i3.95849)]

Observational Study

Rizza G, Glynou K, Elets kaya M. Impact of hepatitis B immunoglobulin mode of administration on treatment experiences of patients after liver transplantation: Results from an online survey. *World J Transplant* 2024; 14(3): 90949 [DOI: [10.5500/wjt.v14.i3.90949](https://doi.org/10.5500/wjt.v14.i3.90949)]

ABOUT COVER

Editorial Board Member of *World Journal of Transplantation*, Zhu-Xu Zhang, PhD, Professor, Departments of Medicine, Pathology, Western University, London, Ontario N6A 5A5, Canada. zhuxu.zhang@lhsc.on.ca

AIMS AND SCOPE

The primary aim of *World Journal of Transplantation* (*WJT*, *World J Transplant*) is to provide scholars and readers from various fields of transplantation with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJT mainly publishes articles reporting research results obtained in the field of transplantation and covering a wide range of topics including bone transplantation, brain tissue transplantation, corneal transplantation, descemet stripping endothelial keratoplasty, fetal tissue transplantation, heart transplantation, kidney transplantation, liver transplantation, lung transplantation, pancreas transplantation, skin transplantation, etc.

INDEXING/ABSTRACTING

The *WJT* is now abstracted and indexed in PubMed, PubMed Central, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The *WJT*'s CiteScore for 2023 is 3.5 and Scopus CiteScore rank 2023: Transplantation is 21/54.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Yan-Liang Zhang, Production Department Director: Xu Guo, Cover Editor: Jia-Ping Yan.

NAME OF JOURNAL

World Journal of Transplantation

ISSN

ISSN 2220-3230 (online)

LAUNCH DATE

December 24, 2011

FREQUENCY

Quarterly

EDITORS-IN-CHIEF

Maurizio Salvadori, Sami Akbulut, Vassilios Papalois, Atul C Mehta

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2220-3230/editorialboard.htm>

PUBLICATION DATE

September 18, 2024

COPYRIGHT

© 2024 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

Disorders of potassium homeostasis after kidney transplantation

Abdelhamid Aboghanem, G V Ramesh Prasad

Specialty type: Transplantation

Provenance and peer review:

Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's classification

Scientific Quality: Grade B, Grade C

Novelty: Grade B, Grade B

Creativity or Innovation: Grade B, Grade B

Scientific Significance: Grade B, Grade C

P-Reviewer: Cabezuelo AS; Varama A

Received: April 21, 2024

Revised: May 29, 2024

Accepted: June 26, 2024

Published online: September 18, 2024

Processing time: 100 Days and 9.7 Hours



Abdelhamid Aboghanem, G V Ramesh Prasad, School of Medicine, University of Toronto, Toronto M5C 2T2, Ontario, Canada

G V Ramesh Prasad, Kidney Transplant Program, St. Michael's Hospital, Toronto M5C 2T2, Ontario, Canada

Corresponding author: G V Ramesh Prasad, MBBS, PhD, Professor, Staff Physician, Kidney Transplant Program, Michael's Hospital, No. 61 Queen Street East, Toronto M5C 2T2, Ontario, Canada. ramesh.prasad@unityhealth.to

Abstract

Disturbances of potassium balance are often encountered when managing kidney transplant recipients (KTR). Both hyperkalemia and hypokalemia may present either as medical emergencies or chronic outpatient abnormalities. Despite the high incidence of hyperkalemia and its potential life-threatening implications, consensus on its management in KTR is lacking. Hypokalemia in KTR is also well-described, although it is given less attention by clinicians compared to hyperkalemia. This article discusses the etiology, pathophysiology and management of both types of potassium disorders in KTR. Once any emergent situation has been corrected, treatment approaches include correcting insulin deficiency if present, adjusting non-immunosuppressive and immunosuppressive medications, eliminating or supplementing potassium as needed, and dietary counselling. Although commonly of multifactorial etiology, ascertaining the specific cause in a particular patient will help guide successful management. Monitoring KTR through regular laboratory testing is essential to detect serious disturbances in potassium balance since patients are often asymptomatic.

Key Words: Balance; Dialysis; Hyperkalemia; Hypokalemia; Kidney; Metabolism; Potassium

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Both hyperkalemia and hypokalemia are usually asymptomatic in kidney transplant recipients but can lead to serious morbidity, so regular monitoring is needed. Since medications are a common cause, dose adjustments or medication changes are often required.

Citation: Aboghanem A, Prasad GVR. Disorders of potassium homeostasis after kidney transplantation. *World J Transplant* 2024; 14(3): 95905

URL: <https://www.wjgnet.com/2220-3230/full/v14/i3/95905.htm>

DOI: <https://dx.doi.org/10.5500/wjt.v14.i3.95905>

INTRODUCTION

Kidney transplantation (KT) is the treatment of choice for end-stage kidney disease (ESKD)[1]. Successful KT improves quality of life and survival for many ESKD patients compared to long-term dialysis[2]. Among the complications faced by kidney transplant recipients (KTR), an increased susceptibility to hyperkalemia occurs compared to non-KTR with similar kidney function[3]. Hyperkalemia increases patient morbidity and possibly cardiovascular mortality, and also adds to healthcare expenses by delaying discharge from hospital whether it occurs during the first or subsequent admissions. The prevalence of hyperkalemia in KTR is estimated to be between 25% and 44%[4]. Hyperkalemia can occur at any time in the post-transplant period. Many clinicians intervene when plasma or serum potassium levels exceed 5.5 mmol/L[5]. Despite the high incidence of hyperkalemia and its potential life-threatening implications, consensus on its management in KTR is lacking. Hypokalemia in KTR is also well-described, although it is given less attention by clinicians compared to hyperkalemia. This article discusses the pathophysiology and management of both types of potassium disorders in KTR. Hyperkalemia is defined here as a plasma potassium ion (K⁺) concentration exceeding 5 mmol/L and hypokalemia as K⁺ less than 3.5 mmol/L.

For this narrative review, we surveyed the published English literature using PubMed and Medline (1965-2024) using the search terms potassium, hyperkalemia, hypokalemia, and transplantation to identify the most relevant articles for inclusion. Criteria for selection included relevance to kidney pathophysiology and clinical practice.

HYPERKALEMIA

Etiology

The major causes of post-transplant hyperkalemia are summarized in [Table 1](#). Frequently prescribed post-transplant medications, including calcineurin inhibitors (CNI), sulfa antibiotics, and antihypertensive agents such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARB), and beta blockers are common etiologic culprits for post-transplant hyperkalemia even in KTR with a well-functioning graft. Simultaneous kidney-pancreas transplant recipients with bladder drainage may have an incidence of up to 73%[4]. Hyperkalemia may be more frequent in KTR with delayed graft function. Dietary non-adherence when present along with other risk factors[5], transcellular K⁺ shifts from uncontrolled diabetes or intraoperative mannitol use, and metabolic acidosis are other common causes[6].

Pathophysiology

Potassium homeostasis: Potassium is the predominant intracellular cation, with a concentration of 140-150 mmol/L intracellularly and 3.5-5 mmol/L extracellularly. Serum K⁺ is slightly elevated compared to plasma K⁺ due to K⁺ release from clotted red blood cells. A high intracellular K⁺ concentration maintained by Na⁺/K⁺-ATPase establishes the resting membrane potential essential for cellular excitability and contraction. K⁺ enters the body through diet, and kaliuresis results in K⁺ leaving the body, with a lesser amount leaving *via* the colon. Since the ratio of intracellular to extracellular K⁺ concentration substantially impacts the resting membrane potential, a stable plasma K⁺ concentration is essential to optimal cellular function[7].

Mannitol: Acute hyperkalemia in the early post-transplant phase is not uncommon. Mannitol is often used during the KT operative procedure as an osmotic diuretic to improve renal blood flow and reduce warm ischemia related injury[8], although its use is controversial[9]. Mannitol can cause intraoperative hyperkalemia[10], even leading to cardiac arrest [11]. Possible mechanisms include hemolysis from its hypertonicity, acidosis from dilution of bicarbonate as a consequence to the desired temporary intravascular volume expansion, and solvent drag[11]. Hypertonic mannitol also decreases sodium reabsorption if significant native kidney function is present, and there may be dilution of plasma proteins, decreased blood viscosity, release of prostaglandins and atrial natriuretic factor, and renin-angiotensin system inhibition[12]. Mannitol through solvent drag moves water and K⁺ out of cells, and this movement is exacerbated by concomitant hyperglycemia. Mannitol use remains popular however due to a reduced incidence of delayed graft function and acute kidney injury[13].

Insulin deficiency: Dietary K⁺ is normally absorbed by the gastrointestinal tract, then rapidly taken up by muscle and liver cells, facilitated by insulin and beta-2 adrenergic receptors. Most K⁺ load is excreted renally, being tightly regulated predominantly in the connecting tubule and cortical collecting duct. Aldosterone, along with adequate distal water and sodium delivery are crucial determinants to renal K⁺ secretion. Dietary K⁺ is not a significant determinant of plasma K⁺ unless renal function is impaired[14]. Sodium reabsorption *via* the epithelial sodium channel (ENaC) establishes the electrical gradient required for K⁺ secretion. Hyperkalemia can thereby result from insulin deficiency, inorganic metabolic acidosis, diminished glomerular filtration rate (GFR), and reduced distal sodium delivery. In KTR, hyper-

Table 1 Causes of hyperkalemia in kidney transplant recipients

Category	Examples
Type of transplant	Combined kidney-pancreas
Immunosuppressive medications	Cyclosporine
	Tacrolimus
Non-immunosuppressive medications	Angiotensin-converting enzyme inhibitors
	Angiotensin II receptor blockers
	Beta-blockers
	Steroidal mineralocorticoid antagonists (eplerenone, spironolactone)
	Non-steroidal mineralocorticoid antagonists (finerenone)
	Potassium-sparing diuretics (amiloride, triamterene)
	Heparin
	Mannitol
	Non-steroidal anti-inflammatory drugs
	Pneumocystis jirovecii pneumonia prophylactic agents (pentamidine, trimethoprim-sulfamethoxazole)
Others	Succinylcholine
	Interstitial fibrosis and tubular atrophy
	Delayed graft function
	Dietary indiscretion ¹
	Hyperglycemia
	Metabolic acidosis
	Type 4 renal tubular acidosis
Urinary tract obstruction	

¹In combination with at least one other factor.

kalemia can however result from type 4 renal tubular acidosis (RTA) from CNI, even in the absence of any of these other risk factors[15]. Insulin deficiency or resistance can hinder the translocation of K⁺ to the intracellular compartment, resulting in post-transplant hyperkalemia along with hyperglycemia, especially in KTR with diabetes[16].

Non-immunosuppressive medications: Medications contribute significantly to hyperkalemia even in KTR with well-functioning grafts. Trimethoprim in trimethoprim/sulfamethoxazole (TMP/SMX) being structurally similar to amiloride and triamterene, competitively blocks ENaC, diminishing the lumen-negative voltage in the cortical distal nephron (CDN) critical to K⁺ secretion[17]. This mechanism holds true for pentamidine, also used for prophylaxis against *Pneumocystis jirovecii* pneumonia (PJP)[18]. Depressed GFR, hyporeninemic hypoaldosteronism, and a low flow rate in the CDN from intravascular volume depletion combine to affect the luminal fluid's osmole content and potentially increase TMP concentration in the CDN, enhancing further its ability to block ENaC. ACE inhibitors and ARB are popular drugs for KTR[19], but increase plasma K⁺ due to impaired K⁺ secretion[20]. Heparin is commonly administered to hospitalized patients. KTR with poor mobility may receive subcutaneous heparin, and complications such as deep vein thrombosis and pulmonary embolism often require intravenous (IV) heparin. Although not specifically described in KTR, both unfractionated and low-molecular-weight heparin selectively reduce aldosterone synthesis, and decrease the number and affinity of adrenal angiotensin II receptors[21,22]. Severe hyperkalemia is more likely when kidney function is impaired or when ACE inhibitors, ARB, or potassium-sparing diuretics are used concomitantly. Beta-blockers are also associated with hyperkalemia due to plasma K⁺ shifts[23] although the evidence for persistent or severe hyperkalemia is low[6].

CNI: CNI (tacrolimus and cyclosporine) are a mainstay of post kidney-transplant immunosuppression, often being prescribed for the life of the allograft. CNI are a well-described cause of hyperkalemia, with up to 32% of KTR receiving cyclosporine experiencing hyperkalemia[24]. Tacrolimus may portend a greater risk than cyclosporine[25]. The sodium chloride cotransporter (NCC)-regulatory kinase (with no lysine) WNK4 is increased[26]. WNK kinases exert their effect on NCC by phosphorylating members of the sterile (STE)-20 superfamily of serine/threonine kinases, specifically the STE20-related proline-alanine-rich-kinase (SPAK) and the oxidative stress response kinase type 1 (OSR1), and they in turn phosphorylate and activate the NCC. WNK4 is the major regulatory kinase of SPAK/OSR1-NCC pathway. CNI increase

phosphorylation of the NCC in the first part of the DCT, thereby maintaining its active state[26]. WNK4 in turn is degraded by binding to Kelch-like 3 (KLHL3)[27] and Cullin 3 proteins as part of a E3 ubiquitin ligase complex. The proper functioning of this ubiquitin ligase complex requires the dephosphorylation of KLHL3, a process mediated by protein phosphatase 3 (or calcineurin). CNI maintain KLHL3 in its phosphorylated, inactive state, consequently reducing the degradation of WNK kinases. Increased NaCl reabsorption by NCC leads to volume expansion to suppress renin and aldosterone release, reducing the number of open ENaC units in the luminal membranes of principal cells in the aldosterone-sensitive distal nephron. Atrial natriuretic peptide released in response to volume expansion suppresses renin release and inhibits hyperkalemia-induced aldosterone secretion. Diminished NaCl delivery to the aldosterone sensitive distal nephron decreases the ability to generate a lumen negative voltage. These kinases also cause renal outer medullary potassium (ROMK) endocytosis from the luminal membrane of principal cells. Mineralocorticoid resistance[28, 29] combined with metabolic acidosis leads to impaired K⁺ secretion and hyperkalemic type 4 RTA. CNI also induce afferent renal arteriolar vasoconstriction and exacerbate AKI[30], reducing K⁺ elimination further. Chronic downregulation of nuclear factor of activated T cells from long-term CNI use leads to renal vasculature hyalinosis, tubular atrophy, interstitial fibrosis, and glomerular thickening[26], all of which associate with worsened renal allograft function[31].

Obstructive uropathy: A type 4 RTA may also occur in patients with obstructive uropathy, a condition to which KTR are prone. In this situation, Type 4 RTA results from a defect in H⁺ and K⁺ secretion in the distal nephron, similar to chronic interstitial nephritis, rather than from aldosterone deficiency[32]. Reduced renal blood flow causes ischemia, and T lymphocytes as well as macrophages enter the interstitium. These cells produce transforming growth factor β , leading to progressive fibrosis and reduced glomerular filtration if the obstruction is left unchecked. Patients with type 4 RTA including KTR are often asymptomatic with a normal urine output, but the associated hyperkalemia can still be severe.

Clinical manifestations

Although hyperkalemia often presents asymptotically, untreated hyperkalemia can quickly cause ascending muscle weakness, paresthesias, decreased reflexes, and ultimately cardiac arrhythmias and fatality[6]. The specific consequences of untreated hyperkalemia to KTR have not been well described. Nonetheless, insights from chronic kidney disease (CKD) populations underscore the importance of maintaining normal serum K⁺ concentrations[33]. Most post-transplant programs perform regular blood testing as part of their routine monitoring, resulting in a greater likelihood of detecting hyperkalemia compared to other CKD patients as a result of ascertainment bias. However, KTR may present to transplant clinics or emergency departments in the context of acute illness, at which time hyperkalemia may be detected as part of their admission screening. All new KTR should be admitted to either an intensive care or step-down unit with available continuous cardiac rhythm monitoring in the immediate post-operative period, due to the risk for hyperkalemia.

The detection of hyperkalemia warrants urgent assessment, even though symptomatic manifestations directly attributable to the hyperkalemia are rare. After excluding pseudohyperkalemia from sample hemolysis[34], which is typically commented in the laboratory report but is not uncommon in KTR who are subject to poor vascular access. It is important to assess if an emergency situation is present through electrocardiogram (ECG) changes, such as peaked T-waves, widened QRS complexes, prolonged QT-interval, and hidden P-waves[35,36]. Considerable variability exists regarding the plasma K⁺ concentration required to induce cardiac toxicity. Increased K⁺ conductance shortens the action potential duration leading to sinus arrest, sinus bradycardia, ventricular fibrillation, and asystole[36].

Management

Cardiac membrane stabilization: An ECG can often be quickly obtained in the hospital immediately post-transplant or even in the outpatient setting, although some outpatient clinics may prefer to send their patients immediately to an emergency department. Successfully handling hyperkalemia revolves around safeguarding against arrhythmias. Intravenous calcium gluconate is commonly used if ECG changes consistent with hyperkalemia are present. Even mild ECG changes can rapidly progress to dangerous arrhythmias. Emergency treatment can be considered even when ECG changes are absent, usually when the K⁺ is around 6.5 mmol/L, and especially when hypocalcemia, acidemia, and/or hyponatremia are also present. For unclear reasons, patients on chronic hemodialysis may tolerate serious hyperkalemia without adverse effects[37], but it is unclear if this benefit exists in KTR despite their long-standing CKD. Calcium directly antagonizes the adverse myocardial effects that hyperkalemia induces, reducing the threshold potential of cardiac myocytes and thereby stabilizing the membrane potential. This beneficial effect does not depend on a change in serum K⁺. A typical dose of calcium gluconate is 1000 mg (or 10 mL of a 10% solution) infused over 2 to 3 minutes under cardiac monitoring. If EKG changes persist, the dose can be repeated after 5 minutes.

Shifting potassium into cells: If the serum K⁺ exceeds 7.0 mmol/L, shifting K⁺ into cells can proceed simultaneously, but shifting K⁺ is usually the second step in managing emergent situations. IV short-acting insulin promotes K⁺ shift into the intracellular space. Due to a fear of hypoglycemia, IV glucose is often administered prior to IV insulin, but great care must be taken to stabilize the cardiac cell membrane first when IV glucose is given prior to administering insulin, since the transient hyperglycemia can shift more K⁺ out of cells and cause a potentially fatal arrhythmia. Some authors suggest using 5 units or 0.1 units/kg with 50 g dextrose as a bolus, or administering dextrose as an infusion[38]. Patients should be monitored closely for hypoglycemia for at least 4 h. Sufficient evidence from randomized trials of therapy are lacking [39]. Pre-transplant hyperkalemia predicts post-transplant hyperkalemia[40], so the plasma K⁺ should be kept under 5.5 mmol/L before transplant surgery, if necessary through an extra session of dialysis. Maximizing the K⁺ gradient through a lower dialysate K⁺ content and increasing the dialysis blood flow rate[41] may enhance K⁺ clearance.

Beta-2 adrenergic receptor agonists enhance activation of Na-K ATPase pumps, shifting K⁺ intracellularly. Nebulized salbutamol is easily available, effective and dose-dependent, acting within 30 minutes and peaking at 60 minutes. Salbutamol at a dose of 10 or 20 mg can reduce plasma K⁺ by about 1 mmol/L for 2 h, and is considered effective therapy [42]. Although data specific to KTR are lacking, side effects include tremor, tachycardia, and headaches, which may confound tacrolimus-related side effects. Another measure to consider is administering sodium bicarbonate. Elevating extracellular bicarbonate levels increases cellular K⁺ uptake, although bicarbonate infusion is generally considered ineffective [43,44] especially in isolation, and risks sodium overload and pulmonary edema. Oral sodium bicarbonate (3-5 g/day) in non-emergent situations may be considered adjunctive when concurrent with metabolic acidosis, but there is sparse evidence for this maneuver in KTR.

Potassium elimination: Once the cardiac cell membrane is stable and K⁺ has shifted intracellularly, focus can then shift to eliminating excess K⁺ from the body. Dialysis is efficient therapy for hyperkalemia [39], so the availability of dialysis support at the time of transplant surgery must be ensured. Vascular access for dialysis may not be immediately available in KTR transplanted preemptively, and for KTR on peritoneal dialysis (PD), inadvertent nicking of the peritoneal membrane may cause leaking of dialysate and necessitate placing a hemodialysis catheter, rather than continuing PD. At the other end of the transplant life spectrum, patients with failing renal allografts may also require urgent dialysis for hyperkalemia in the absence of viable access, such as from a clotted or immature fistula or graft. Removing K⁺ *via* the transplanted kidney by a loop diuretic such as furosemide or bumetanide is often employed, even in the early post-transplant setting. Some evidence of existing or establishing kidney function such as measurable urine output is required however, as well as an adequate blood pressure. Loop diuretics may be used in chronic hyperkalemia in normovolemic or hypervolemic patients, in addition to adding other drugs such as thiazides [45].

Fludrocortisone promotes potassium secretion and can help lower plasma K⁺ concentration [46]. Evidence for efficacy in KTR is limited primarily to case reports. At a dose of 0.1 mg/day, both acute and chronic hyperkalemia can be effectively managed [47]. Fludrocortisone may address tacrolimus-induced aldosterone resistance, with normokalemia achievable quickly [48]. Since fludrocortisone causes fluid retention, it may be most useful in early post-transplant patients who are also intravascularly volume depleted.

The gastrointestinal tract can also be a useful route for K⁺ removal. Commonly used agents in the current era include patiromer and sodium zirconium cyclosilicate (ZS-9), with the use of sodium polystyrene sulfonate largely abandoned despite its efficacy with sorbitol, due to concerns over the possibility of intestinal ischemia and thrombosis, leading to bowel necrosis [49]. Patiromer is being used with increasing comfort in KTR based on published clinical experiences [50]. Patiromer is an organic potassium-binding polymer employing calcium as the exchange ion especially in the colon, and so is not particularly helpful in the acute setting. Gastrointestinal side effects are usually limited, but patiromer can cause hypomagnesemia and affect the bioavailability of other drugs [6]. However, there is no clear evidence to-date of interference with immunosuppressive medications. ZS-9 facilitates exchange of H⁺ and Na⁺ for K⁺ and NH₄⁺ throughout the gastrointestinal tract, acting one hour after ingestion, and so may be more useful in the acute setting both for KTR [51] and hospitalized patients more generally [52]. There is no appreciable impact on tacrolimus pharmacokinetics [53]. However, cost remains a concern for using both patiromer and ZS-9.

Adjusting medications: Besides administering new therapies such as those outlined above, adjusting existing medications through discontinuation, switch, or dose reduction is also an important part of hyperkalemia management. TMP and antihypertensive agents are often the first targets of change for clinicians. While TMP/SMX remains the standard for PJP prevention, alternative agents such as dapsone or atovaquone are equally effective. Hyperkalemia is not necessarily dependent on the dose of TMP [54]. Thrice weekly TMP/SMX in the first post-transplant year is a safe and an effective regimen to prevent PJP [55]. Antihypertensives affecting the renin-angiotensin-aldosterone system are typically avoided early post-transplant but may be warranted later for patients with cardiovascular comorbidities. Beta blockers are not typically discontinued early post-transplant unlike ACE or ARB. Adding patiromer or ZS-9 might facilitate continuing these medications over the long term. In cases of mild to moderate hyperkalemia, such medication adjustment can help normalize serum K⁺ levels without the need for total discontinuation.

Changes in immunosuppressive medication are rarely pursued in response to hyperkalemia given the effectiveness of all the preceding measures, since immunosuppressive medication changes might increase risks for new side effects or even acute rejection. Similarly, the risk of hyperkalemia is typically not considered when selecting de-novo immunosuppressive regimens. Nonetheless, some studies report a lower incidence of hyperkalemia with drugs such as sirolimus [56, 57], everolimus [58], and belatacept [59,60], so switches made for this indication are at theoretically feasible.

Dietary modification: Dietary modification can be a very useful adjunct in managing post-transplant hyperkalemia. All KTR with a measured plasma or serum K⁺ greater than 5.0 mmol/L should receive dedicated dietician counseling, customized to their ethnic and sociocultural background, and be given appropriate dietary information sheets. Repeated consultations might be required if hyperkalemia persists. Such counseling may help prevent visits to the emergency department for severe hyperkalemia.

HYPOKALEMIA

Hypokalemia is characterized by a plasma K⁺ concentration below 3.5 mmol/L, and can be life-threatening when below < 2.5 mEq/L. In an outpatient population undergoing laboratory testing, nearly 14% exhibit mild hypokalemia. The incidence of hypokalemia is less than that of hypomagnesemia in stable outpatient KTR [61]. Additionally, about 20% of

hospitalized patients generally are found to have hypokalemia, but only a small fraction of these instances is clinically significant.

Etiology and pathogenesis

Hypokalemia can be experimentally induced[62], but is rarely seen in healthy subjects. The kidney can minimize potassium excretion to 5 to 25 mmol *per* day in the presence of total body potassium depletion[62]. Reducing potassium intake to 20 mmol *per* day therefore seldom results in significant hypokalemia. Enhanced insulin availability promotes K⁺ entry into skeletal muscle and hepatic cells by increased Na-K-ATPase pump activity, such as when exogenous insulin is administered in severely hyperglycemic states even when there is initial normokalemia or hyperkalemia. However, hypokalemia arising from insulin overdose is rare. Furthermore, endogenous insulin release in response to carbohydrate intake, as observed in refeeding syndrome or administration of dextrose may contribute to hypokalemia. IV potassium is therefore administered using a saline solution rather than dextrose[63-65]. Elevated beta-adrenergic activity and exercise-induced catecholamine surges are some other causes[66,67], though these events are not specific to KTR. Hypokalemia is more severe in patients with pre-existing hypokalemia receiving diuretic therapy[68], and is dose-dependent. Increased gastrointestinal losses due to vomiting, diarrhea, laxatives, or nasogastric tube drainage lead to metabolic alkalosis and substantial urinary potassium losses. Diarrhea from any cause as well as secretions from villous adenomas can be associated with relatively high K⁺ concentrations due to hyperchloremic metabolic acidosis.

Urinary K⁺ excretion, mainly regulated by principal cells in the connecting tubule and cortical collecting tubule, is a key determinant of K⁺ balance. Increased mineralocorticoid activity creates an electronegative lumen that facilitates passive K⁺ secretion into the tubular lumen through potassium channels such as ROMK. Hypokalemia may result from polyuria when intravascular volume depletion enhances aldosterone secretion. Reduced activity of K⁺ secretory channels potentially mediated by increased angiotensin II activity may explain the inconsistent occurrence of hypokalemia in primary aldosteronism[69].

The use of both sirolimus[69,70] and everolimus[71] has been associated with hypokalemia. Hypokalemic nephropathy can occur, with tubular vacuolization, reversible with sirolimus discontinuation[72]. Mammalian target of rapamycin, which sirolimus inhibits, plays a role in tubular epithelial cell integrity and regeneration[72]. Although an incidence of up to 50% has been reported with everolimus in antitumour regimens[73], the incidence is likely in the 5%-10% range in KTR [70]. Hypokalemia can occur in KTR due to native renal artery stenosis[74]. Primary aldosteronism may be unmasked by KT[75]. The incidence of hypokalemia in KTR receiving thiazide diuretics can approach 30%[45]. Patients receiving hemodialysis against a low K⁺ bath, those on PD prior to receiving their transplant, and those requiring plasmapheresis, for example as part of treatment for antibody-mediated rejection, may be at greater risk for hypokalemia. Low dietary potassium intake from failure to unlearn dialysis restrictions post-transplant may lead to hypokalemia, usually when combined with factors.

The major causes of post-transplant hypokalemia are summarized in [Table 2](#).

Clinical manifestations

Hypokalemia-induced ECG alterations include ST segment depression, diminished T wave amplitude, and increased U wave amplitude, particularly in lateral precordial leads V4 to V6, and QT interval prolongation. Skeletal muscle weakness and atrial fibrillation are sometimes noted. Prolonged hypokalemia impairs urine concentrating ability, and can lead to hypokalemic nephropathy and elevations in blood pressure, as well as decreased phosphate reabsorption. Hypokalemia also reduces insulin secretion and can contribute to glucose intolerance and thiazide-associated diabetes, although whether hypokalemia contributes to the incidence of post-transplant diabetes (PTDM) is unknown.

Management

Immediate measures: Use of balanced solutions rather than normal saline as replacement fluids can be considered preventative in the early post-transplant period since concerns regarding hyperkalemia are minimal[76,77]. The cause for hypokalemia often evident from factors like vomiting, diarrhea, or diuretic therapy. If serum K⁺ is below 2.5 mEq/L and there is severe muscle weakness or ECG changes, then prompt treatment is indicated. Continuous cardiac monitoring is recommended if there are ECG changes linked to hypokalemia, or underlying cardiac conditions that increase arrhythmia risk in the context of hypokalemia[78,79]. Treating the underlying cause of gastrointestinal losses, reducing or discontinuing diuretics, and supplementing dietary potassium intake are some basic measures to be undertaken. Hospital units will typically strictly guide the constitution of IV K⁺ formulations and their permissible rate of administration.

Potassium replacement: Continued replacement over days is required to address the marked total body potassium deficit, taking care to prevent transient hyperkalemia during repletion. Serum K⁺ should be quickly raised to a safe level, followed by slower deficit replacement. Although there are no guidelines specific to KTR, the replacement rate should account for the patient's GFR. For patients with uncontrolled PTDM and hyperkalemia, insulin therapy and fluid replacement should lower serum K⁺ towards the deficit-appropriate level, and potassium supplementation can begin when the serum K⁺ is 4.5 mEq/L or lower. For patients presenting with hypokalemia, insulin therapy is delayed until potassium is above 3.3 mEq/L[80,81].

Long-term supplementation: For long-term management, a variety of oral potassium supplements in different dosage strengths are available, with the choice depending upon the presence of metabolic acidosis or hypophosphatemia[81]. Slow-release tablets have better tolerance but carry a low risk of gastrointestinal intolerance especially with microencapsulated preparations[82]. Other options include replacing loop or thiazide diuretics with potassium-sparing diuretics such as amiloride or triamterene, and adding aldosterone antagonists such as spironolactone or eplerenone if renal K⁺

Table 2 Causes of hypokalemia in kidney transplant recipients

Category	Example
Potassium loss	
Gastrointestinal	Vomiting Diarrhea Intestinal malabsorption Colostomy
Renal	Hyperkalemia Hyperreninemia Hyperaldosteronism Renal tubular acidosis (Type 1, 2) Hypomagnesemia
Medications	Sirolimus Everolimus Loop diuretics Thiazide diuretics Mineralocorticoids
Inadequate Potassium Intake	Poor oral intake Dietary indiscretion ¹ Total parenteral nutrition
Intracellular Potassium Shift	Metabolic alkalosis Dextrose solution Insulin therapy
Others	Dialysis using low potassium bath Peritoneal dialysis Plasmapheresis

¹In combination with at least one other factor.

wasting is present, although careful monitoring is required. Magnesium deficiency is frequently associated with hypokalemia, and if unrecognized can result in refractory hypokalemia. Reduced intracellular magnesium prevents inhibition of ROMK channels, increasing potassium secretion[83]. While magnesium deficiency alone is insufficient to cause hypokalemia, IV or oral supplementation can be considered if hypomagnesemia is noted. Not all transplant programs routinely monitor post-transplant serum magnesium concentrations, but they should be measured if hypokalemia is noted.

Dietary modification: Dietary intervention for hypokalemia may be less effective due to the predominantly potassium phosphate or potassium citrate form in dietary potassium[84]. Increased fruit intake may have limited impact as well since a large consumption would be required[85]. However, providing dietary advice can still be considered as a part of the overall nutrition plan (Table 3), since hypokalemic patients are often undernourished as well. Food literacy and social support are particularly relevant[86]. Unfortunately there have been no clinical trials of dietary intervention in the context of electrolyte management in KTR.

All KTR should undergo regular laboratory testing that includes serum electrolyte measurement. One example of such a monitoring strategy includes daily testing until hospital discharge, twice weekly to the end of month three, weekly to the end of month six, every two weeks to the end of month nine, monthly to the end of year two, and then once every three months thereafter, with added testing performed as necessary. Some transplant programs monitor patients remotely, so a clear action plan for incidentally detected emergencies should be developed in advance. A brief summary of some common preventative and management strategies for disorders of K⁺ homeostasis in KTR is provided in Table 4.

Table 3 Common examples of food sources containing potassium

Potassium content ¹		
Low	Medium	High
Apple juice	Grape juice	Orange juice
Cranberry juice	Grapefruit juice	Prune juice
Lemon juice	Pineapple juice	Apricots
Peach nectar	Apple	Banana
Pear nectar	Cherries	Breadfruit
Blackberries	Lychees	All dried fruits
Blueberries	Plum	Guava
Raspberries	Pear	Honeydew
Strawberries	Pomelo	Jackfruit
Asparagus	Starfruit	Kiwi
Bamboo shoots	Artichoke	Mango
Broccoli	Beets	Nectarine
Cabbage	Carrot	Papaya
Cucumber	Cauliflower	Persimmon
Eggplant	Corn	Pomegranate
Beans	Kale	Lentils
Lettuce	Mustard greens	Mushrooms (cooked)
Mushrooms (raw)	Peas	Okra
Onion	Spinach (raw)	Potatoes
Pepper	Zucchini	Spinach (cooked)
Radish	Custard	Sweet potato
Rhubarb	Cream soup	Tomato
Tofu	Ice cream	Water chestnut (fresh)
Turnip	Milk	Winter squash
Water chestnut (canned)	Yogurt	Yam

¹Specific amounts allowed should be discussed with a transplant dietician as part of an overall management plan.

Table 4 Common preventive and management strategies for post-transplant hyperkalemia and hypokalemia

	Hyperkalemia	Hypokalemia
Pre-transplant	Hold ACE inhibitor or ARB Add extra session of hemodialysis	Hold loop and thiazide diuretics, if applicable
Early post-transplant	Obtain ECG and administer IV calcium gluconate if appropriate Add extra session of hemodialysis Correct insulin deficiency Correct metabolic acidosis Add loop diuretic Avoid potassium-sparing diuretics Address constipation	Obtain ECG and administer IV potassium chloride if appropriate Use high K ⁺ bath for hemodialysis if needed Add KCl to replacement fluid Correct metabolic alkalosis Avoid loop diuretic Add oral potassium supplement Consult dietician

	Minimize use of heparin	
	Delay introducing sulfa antibiotic	
	Consult dietician	
Late post-transplant	Reduce or hold ACE inhibitor or ARB, potassium-sparing diuretic	Correct underlying cause, e.g., diarrhea
	Rule out obstruction	Add ACE inhibitor or ARB, potassium sparing diuretic
	Reduce or hold sulfa antibiotic, or switch to another prophylactic drug for <i>Pneumocystis jirovecii</i>	Add oral potassium supplement
	Add fludrocortisone	Identify and correct magnesium deficiency
	Correct metabolic acidosis	Consult dietician
	Optimize glycemic control	
	Add oral patiromer or sodium zirconium cyclosilicate	
	Consult dietician	

ACE: Angiotensin-converting enzyme; ARB: Angiotensin II receptor blockers; ECG: Electrocardiogram.

CONCLUSION

Both hyperkalemia and hypokalemia are important electrolyte disturbances encountered when managing KTR, and can present either as medical emergencies or chronic outpatient abnormalities. Experience from the general population and patients with CKD in native kidneys is typically extrapolated to pathophysiology in the transplant kidney and thereby to KTR. Although commonly of multifactorial etiology, ascertaining the specific cause in a particular patient will help guide successful management. Regular monitoring through laboratory testing is essential to detect serious disturbances in K⁺ metabolism since patients are often asymptomatic. Transcellular shifting, potassium removal or supplementation, and longer-term measures including adjusting immunosuppressive and non-immunosuppressive medications as well as dietary counseling all play a role in ensuring optimal post-transplant patient outcomes.

FOOTNOTES

Author contributions: Aboghanem A critically reviewed and appraised the literature and wrote the paper; Prasad GVR designed the study, critically reviewed and appraised the literature, and wrote the paper. Both authors read and approved the final manuscript.

Conflict-of-interest statement: The authors have no conflict of interest to declare in relation to the manuscript.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country of origin: Canada

ORCID number: G V Ramesh Prasad [0000-0003-1576-7696](https://orcid.org/0000-0003-1576-7696).

S-Editor: Liu H

L-Editor: A

P-Editor: Zhang L

REFERENCES

- 1 Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, Held PJ, Port FK. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. *N Engl J Med* 1999; **341**: 1725-1730 [PMID: 10580071 DOI: 10.1056/NEJM199912023412303]
- 2 Tonelli M, Wiebe N, Knoll G, Bello A, Browne S, Jadhav D, Klarenbach S, Gill J. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. *Am J Transplant* 2011; **11**: 2093-2109 [PMID: 21883901 DOI: 10.1111/j.1600-6143.2011.03686.x]
- 3 Jones JW, Gruessner RW, Gores PF, Matas AJ. Hypoaldosteronemic hyporeninemic hyperkalemia after renal transplantation. *Transplantation* 1993; **56**: 1013-1015 [PMID: 8212180]

- 4 **Kaplan B**, Wang Z, Abecassis MM, Fryer JP, Stuart FP, Kaufman DB. Frequency of hyperkalemia in recipients of simultaneous pancreas and kidney transplants with bladder drainage. *Transplantation* 1996; **62**: 1174-1175 [PMID: 8900321 DOI: 10.1097/00007890-199610270-00025]
- 5 **Alfonzo AV**, Isles C, Geddes C, Deighan C. Potassium disorders--clinical spectrum and emergency management. *Resuscitation* 2006; **70**: 10-25 [PMID: 16600469 DOI: 10.1016/j.resuscitation.2005.11.002]
- 6 **Rizk JG**, Lazo JG Jr, Quan D, Gabardi S, Rizk Y, Streja E, Kovessy CP, Kalantar-Zadeh K. Mechanisms and management of drug-induced hyperkalemia in kidney transplant patients. *Rev Endocr Metab Disord* 2021; **22**: 1157-1170 [PMID: 34292479 DOI: 10.1007/s11154-021-09677-7]
- 7 **Palmer BF**. Regulation of Potassium Homeostasis. *Clin J Am Soc Nephrol* 2015; **10**: 1050-1060 [PMID: 24721891 DOI: 10.2215/CJN.08580813]
- 8 **Lugo-Baruqui JA**, Ayyathurai R, Sriram A, Pragatheeshwar KD. Use of Mannitol for Ischemia Reperfusion Injury in Kidney Transplant and Partial Nephrectomies-Review of Literature. *Curr Urol Rep* 2019; **20**: 6 [PMID: 30685826 DOI: 10.1007/s11934-019-0868-6]
- 9 **Reiterer C**, Hu K, Sljivic S, Falkner von Sonnenburg M, Fleischmann E, Kainz A, Kabon B. Mannitol and renal graft injury in patients undergoing deceased donor renal transplantation - a randomized controlled clinical trial. *BMC Nephrol* 2020; **21**: 307 [PMID: 32723374 DOI: 10.1186/s12882-020-01961-z]
- 10 **Sharma J**, Salhotra R. Mannitol-induced intraoperative hyperkalemia, a little-known clinical entity. *J Anaesthesiol Clin Pharmacol* 2012; **28**: 546-547 [PMID: 23225957 DOI: 10.4103/0970-9185.101965]
- 11 **Zheng H**, Cao X, Gao F, Li X, Wan L, Luo A. Hyperkalemic cardiac arrest induced by mannitol administration during craniotomy: A case report and review of the literature. *Front Surg* 2022; **9**: 1019101 [PMID: 36303859 DOI: 10.3389/fsurg.2022.1019101]
- 12 **Laar SCV**, Schouten GN, IJzermans JNM, Minnee RC. Effect of Mannitol on Kidney Function After Kidney Transplantation: A Systematic Review and Meta-Analysis. *Transplant Proc* 2021; **53**: 2122-2132 [PMID: 34412911 DOI: 10.1016/j.transproceed.2021.07.001]
- 13 **Lauzurica R**, Teixidó J, Serra A, Torguet P, Bonet J, Bonal J, Borrás M, Romero R, Caralps A. Hydration and mannitol reduce the need for dialysis in cadaveric kidney transplant recipients treated with CyA. *Transplant Proc* 1992; **24**: 46-47 [PMID: 1539337]
- 14 **Palmer BF**. A physiologic-based approach to the evaluation of a patient with hyperkalemia. *Am J Kidney Dis* 2010; **56**: 387-393 [PMID: 20493606 DOI: 10.1053/j.ajkd.2010.01.020]
- 15 **Keven K**, Ozturk R, Sengul S, Kutlay S, Ergun I, Erturk S, Erbay B. Renal tubular acidosis after kidney transplantation--incidence, risk factors and clinical implications. *Nephrol Dial Transplant* 2007; **22**: 906-910 [PMID: 17210594 DOI: 10.1093/ndt/gfl714]
- 16 **Rosenbaum R**, Hoffsten PE, Cryer P, Klahr S. Hyperkalemia after renal transplantation. Occurrence in a patient with insulin-dependent diabetes. *Arch Intern Med* 1978; **138**: 1270-1272 [PMID: 354542 DOI: 10.1001/archinte.138.8.1270]
- 17 **Velázquez H**, Perazella MA, Wright FS, Ellison DH. Renal mechanism of trimethoprim-induced hyperkalemia. *Ann Intern Med* 1993; **119**: 296-301 [PMID: 8328738 DOI: 10.7326/0003-4819-119-4-199308150-00008]
- 18 **Kleyman TR**, Roberts C, Ling BN. A mechanism for pentamidine-induced hyperkalemia: inhibition of distal nephron sodium transport. *Ann Intern Med* 1995; **122**: 103-106 [PMID: 7992983 DOI: 10.7326/0003-4819-122-2-199501150-00004]
- 19 **Hiremath S**, Fergusson DA, Fergusson N, Bennett A, Knoll GA. Renin-Angiotensin System Blockade and Long-term Clinical Outcomes in Kidney Transplant Recipients: A Meta-analysis of Randomized Controlled Trials. *Am J Kidney Dis* 2017; **69**: 78-86 [PMID: 27712852 DOI: 10.1053/j.ajkd.2016.08.018]
- 20 **Mitterbauer C**, Heinze G, Kainz A, Kramar R, Hörl WH, Oberbauer R. ACE-inhibitor or AT2-antagonist therapy of renal transplant recipients is associated with an increase in serum potassium concentrations. *Nephrol Dial Transplant* 2008; **23**: 1742-1746 [PMID: 18234845 DOI: 10.1093/ndt/gfm864]
- 21 **Oster JR**, Singer I, Fishman LM. Heparin-induced aldosterone suppression and hyperkalemia. *Am J Med* 1995; **98**: 575-586 [PMID: 7778574 DOI: 10.1016/s0002-9343(99)80017-5]
- 22 **Amdetsion GY**, Gudeta A, Lumley G, Sagoo H, Aliledhin E. Heparin-induced hyperkalemia, can LMWH cause hyperkalemia? A systematic review. *EJHaem* 2023; **4**: 1110-1116 [PMID: 38024642 DOI: 10.1002/jha2.801]
- 23 **McCauley J**, Murray J, Jordan M, Scantlebury V, Vivas C, Shapiro R. Labetalol-induced hyperkalemia in renal transplant recipients. *Am J Nephrol* 2002; **22**: 347-351 [PMID: 12169866 DOI: 10.1159/000065225]
- 24 **Pirsch JD**, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. *Transplantation* 1997; **63**: 977-983 [PMID: 9112351 DOI: 10.1097/00007890-199704150-00013]
- 25 **Higgins R**, Ramaiyan K, Dasgupta T, Kanji H, Fletcher S, Lam F, Kashi H. Hyponatraemia and hyperkalaemia are more frequent in renal transplant recipients treated with tacrolimus than with cyclosporin. Further evidence for differences between cyclosporin and tacrolimus nephrotoxicities. *Nephrol Dial Transplant* 2004; **19**: 444-450 [PMID: 14736972 DOI: 10.1093/ndt/gfg515]
- 26 **Hoorn EJ**, Walsh SB, McCormick JA, Fürstenberg A, Yang CL, Roeschel T, Paliege A, Howie AJ, Conley J, Bachmann S, Unwin RJ, Ellison DH. The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. *Nat Med* 2011; **17**: 1304-1309 [PMID: 21963515 DOI: 10.1038/nm.2497]
- 27 **Ishizawa K**, Wang Q, Li J, Yamazaki O, Tamura Y, Fujigaki Y, Uchida S, Lifton RP, Shibata S. Calcineurin dephosphorylates Kelch-like 3, reversing phosphorylation by angiotensin II and regulating renal electrolyte handling. *Proc Natl Acad Sci U S A* 2019; **116**: 3155-3160 [PMID: 30718414 DOI: 10.1073/pnas.1817281116]
- 28 **Heering PJ**, Kurschat C, Vo DT, Klein-Vehne N, Fehsel K, Ivens K. Aldosterone resistance in kidney transplantation is in part induced by a down-regulation of mineralocorticoid receptor expression. *Clin Transplant* 2004; **18**: 186-192 [PMID: 15016134 DOI: 10.1046/j.1399-0012.2003.00154.x]
- 29 **Deppe CE**, Heering PJ, Viengchareun S, Grabensee B, Farman N, Lombès M. Cyclosporine a and FK506 inhibit transcriptional activity of the human mineralocorticoid receptor: a cell-based model to investigate partial aldosterone resistance in kidney transplantation. *Endocrinology* 2002; **143**: 1932-1941 [PMID: 11956176 DOI: 10.1210/endo.143.5.8821]
- 30 **Olyaei AJ**, de Mattos AM, Bennett WM. Immunosuppressant-induced nephropathy: pathophysiology, incidence and management. *Drug Saf* 1999; **21**: 471-488 [PMID: 10612271 DOI: 10.2165/00002018-199921060-00004]
- 31 **Remuzzi G**, Perico N. Cyclosporine-induced renal dysfunction in experimental animals and humans. *Kidney Int Suppl* 1995; **52**: S70-S74 [PMID: 8587288]
- 32 **Battle DC**, Arruda JA, Kurtzman NA. Hyperkalemic distal renal tubular acidosis associated with obstructive uropathy. *N Engl J Med* 1981; **304**: 373-380 [PMID: 7453754 DOI: 10.1056/NEJM198102123040701]
- 33 **Thomsen RW**, Nicolaisen SK, Hasvold P, Sanchez RG, Pedersen L, Adelborg K, Egstrup K, Egffjord M, Sørensen HT. Elevated potassium

- levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a Danish population-based cohort study. *Nephrol Dial Transplant* 2018; **33**: 1610-1620 [PMID: 29177463 DOI: 10.1093/ndt/gfx312]
- 34 **Meng QH**, Wagar EA. Pseudohyperkalemia: A new twist on an old phenomenon. *Crit Rev Clin Lab Sci* 2015; **52**: 45-55 [PMID: 25319088 DOI: 10.3109/10408363.2014.966898]
- 35 **Teymourli N**, Mesbah S, Navabian SMH, Shekouh D, Najafabadi MM, Norouzkhani N, Poudineh M, Qadirifard MS, Mehrtabar S, Deravi N. ECG frequency changes in potassium disorders: a narrative review. *Am J Cardiovasc Dis* 2022; **12**: 112-124 [PMID: 35873184]
- 36 **Webster A**, Brady W, Morris F. Recognising signs of danger: ECG changes resulting from an abnormal serum potassium concentration. *Emerg Med J* 2002; **19**: 74-77 [PMID: 11777886 DOI: 10.1136/emj.19.1.74]
- 37 **Gasparini A**, Evans M, Barany P, Xu H, Jernberg T, Årnlov J, Lund LH, Carrero JJ. Plasma potassium ranges associated with mortality across stages of chronic kidney disease: the Stockholm CREAtinine Measurements (SCREAM) project. *Nephrol Dial Transplant* 2019; **34**: 1534-1541 [PMID: 30085251 DOI: 10.1093/ndt/gfy249]
- 38 **Moussavi K**, Fitter S, Gabrielson SW, Koyfman A, Long B. Management of Hyperkalemia With Insulin and Glucose: Pearls for the Emergency Clinician. *J Emerg Med* 2019; **57**: 36-42 [PMID: 31084947 DOI: 10.1016/j.jemermed.2019.03.043]
- 39 **Mahoney BA**, Smith WA, Lo DS, Tsoi K, Tonelli M, Clase CM. Emergency interventions for hyperkalaemia. *Cochrane Database Syst Rev* 2005; **2005**: CD003235 [PMID: 15846652 DOI: 10.1002/14651858.CD003235.pub2]
- 40 **de Vries BCS**, Berger SP, Bakker SJL, de Borst MH, de Jong MFC. Pre-Transplant Plasma Potassium as a Potential Risk Factor for the Need of Early Hyperkalaemia Treatment after Kidney Transplantation: A Cohort Study. *Nephron* 2021; **145**: 63-70 [PMID: 33212442 DOI: 10.1159/000511404]
- 41 **Gutzwiller JP**, Schneditz D, Huber AR, Schindler C, Garbani E, Zehnder CE. Increasing blood flow increases kt/V(urea) and potassium removal but fails to improve phosphate removal. *Clin Nephrol* 2003; **59**: 130-136 [PMID: 12608556 DOI: 10.5414/cnp59130]
- 42 **Batterink J**, Cessford TA, Taylor RA. Pharmacological interventions for the acute management of hyperkalaemia in adults. *Cochrane Database Syst Rev* 2015; **10**: CD010344 [PMID: 35658162 DOI: 10.1002/14651858.CD010344.pub2]
- 43 **Allon M**, Shanklin N. Effect of bicarbonate administration on plasma potassium in dialysis patients: interactions with insulin and albuterol. *Am J Kidney Dis* 1996; **28**: 508-514 [PMID: 8840939 DOI: 10.1016/s0272-6386(96)90460-6]
- 44 **Blumberg A**, Weidmann P, Shaw S, Gnädinger M. Effect of various therapeutic approaches on plasma potassium and major regulating factors in terminal renal failure. *Am J Med* 1988; **85**: 507-512 [PMID: 3052050 DOI: 10.1016/s0002-9343(88)80086-x]
- 45 **Taber DJ**, Srinivas TM, Pilch NA, Meadows HB, Fleming JN, McGillicuddy JW, Bratton CF, Thomas B, Chavin KD, Baliga PK, Egede LE. Are thiazide diuretics safe and effective antihypertensive therapy in kidney transplant recipients? *Am J Nephrol* 2013; **38**: 285-291 [PMID: 24061145 DOI: 10.1159/000355135]
- 46 **Gama RM**, Makanjuola D, Wahba M, Quan V, Phanish M. Fludrocortisone Is an Effective Treatment for Hyperkalaemic Metabolic Acidosis in Kidney Transplant Recipients on Tacrolimus: A Case Series. *Nephron* 2022; **146**: 190-196 [PMID: 34784594 DOI: 10.1159/000519670]
- 47 **Marfo K**, Glicklich D. Fludrocortisone therapy in renal transplant recipients with persistent hyperkalemia. *Case Rep Transplant* 2012; **2012**: 586859 [PMID: 23259135 DOI: 10.1155/2012/586859]
- 48 **Sivakumar V**, Sriramnaveen P, Krishna C, Manjusha Y, Reddy YS, Sridhar N, Subramanian S. Role of fludrocortisone in the management of tacrolimus-induced hyperkalemia in a renal transplant recipient. *Saudi J Kidney Dis Transpl* 2014; **25**: 149-151 [PMID: 24434399 DOI: 10.4103/1319-2442.124539]
- 49 **Noel JA**, Bota SE, Petreich W, Garg AX, Carrero JJ, Harel Z, Tangri N, Clark EG, Komenda P, Sood MM. Risk of Hospitalization for Serious Adverse Gastrointestinal Events Associated With Sodium Polystyrene Sulfonate Use in Patients of Advanced Age. *JAMA Intern Med* 2019; **179**: 1025-1033 [PMID: 31180477 DOI: 10.1001/jamainternmed.2019.0631]
- 50 **Schnelle K**, Winters H, Pesavento T, Singh P. Largest Experience of Safety and Efficacy of Patiromer in Solid Organ Transplant. *Transplant Direct* 2020; **6**: e595 [PMID: 32851128 DOI: 10.1097/TXD.0000000000001037]
- 51 **Shockey W**, Wiegel JJ, Parajuli S, Garg N, Swanson KJ, Mandelbrot DA. Potassium-lowering effects of sodium zirconium cyclosilicate in the early post-transplant period. *Clin Transplant* 2024; **38**: e15156 [PMID: 37812572 DOI: 10.1111/ctr.15156]
- 52 **Sullivan E**, Ruegger M, Dunne I, Sutaria N, Towers WF. Comparison of effectiveness and safety of sodium polystyrene sulfonate and sodium zirconium cyclosilicate for treatment of hyperkalemia in hospitalized patients. *Am J Health Syst Pharm* 2023; **80**: 1238-1246 [PMID: 37335862 DOI: 10.1093/ajhp/zxad137]
- 53 **Winstead RJ**, Demehin M, Yakubu I, Song C, Brown A, Levy M, Gupta G. Sodium zirconium cyclosilicate use in solid organ transplant recipients and its effect on potassium and immunosuppression. *Clin Transplant* 2020; **34**: e13791 [PMID: 31991491 DOI: 10.1111/ctr.13791]
- 54 **Perazella MA**, Mahnensmith RL. Trimethoprim-sulfamethoxazole: hyperkalemia is an important complication regardless of dose. *Clin Nephrol* 1996; **46**: 187-192 [PMID: 8879854]
- 55 **Prasad GVR**, Beckley J, Mathur M, Gunasekaran M, Nash MM, Rapi L, Huang M, Zaltzman JS. Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation. *BMC Infect Dis* 2019; **19**: 311 [PMID: 30953458 DOI: 10.1186/s12879-019-3944-0]
- 56 **MacDonald AS**; RAPAMUNE Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. *Transplantation* 2001; **71**: 271-280 [PMID: 11213073 DOI: 10.1097/00007890-200101270-00019]
- 57 **Johnson RW**, Kreis H, Oberbauer R, Brattström C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. *Transplantation* 2001; **72**: 777-786 [PMID: 11571437 DOI: 10.1097/00007890-200109150-00007]
- 58 **Chapman WC**, Brown RS Jr, Chavin KD, Sudan D, Koneru B, Junge G, Dong G, Patel D, Teperman L, Fung JJ. Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation. *Transplantation* 2017; **101**: 341-349 [PMID: 28121741 DOI: 10.1097/TP.0000000000001524]
- 59 **Rostaing L**, Massari P, Garcia VD, Mancilla-Urrea E, Nainan G, del Carmen Rial M, Steinberg S, Vincenti F, Shi R, Di Russo G, Thomas D, Grinyó J. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. *Clin J Am Soc Nephrol* 2011; **6**: 430-439 [PMID: 21051752 DOI: 10.2215/CJN.05840710]
- 60 **Gupta G**, Regmi A, Kumar D, Posner S, Posner MP, Sharma A, Cotterell A, Bhati CS, Kimball P, Massey HD, King AL. Safe Conversion From Tacrolimus to Belatacept in High Immunologic Risk Kidney Transplant Recipients With Allograft Dysfunction. *Am J Transplant* 2015; **15**: 2726-2731 [PMID: 25988397 DOI: 10.1111/ajt.13322]

- 61 **Duni A**, Koutlas V, Tsitouridis A, Tzalavra E, Oikonomaki T, Kitsos A, Rapsomanikis KP, Alekos J, Tatsis V, Pappas C, Mitsis M, Dounousi E. Longitudinal Assessment of Electrolyte Disorders in a Cohort of Chronic Stable Kidney Transplant Recipients. *Transplant Proc* 2021; **53**: 2786-2792 [PMID: 34690001 DOI: 10.1016/j.transproceed.2021.09.012]
- 62 **SQUIRES RD**, HUTH EJ. Experimental potassium depletion in normal human subjects. I. Relation of ionic intakes to the renal conservation of potassium. *J Clin Invest* 1959; **38**: 1134-1148 [PMID: 13664789 DOI: 10.1172/JCI103890]
- 63 **Adrogué HJ**, Lederer ED, Suki WN, Eknoyan G. Determinants of plasma potassium levels in diabetic ketoacidosis. *Medicine (Baltimore)* 1986; **65**: 163-172 [PMID: 3084904 DOI: 10.1097/00005792-198605000-00004]
- 64 **Bradberry SM**, Vale JA. Disturbances of potassium homeostasis in poisoning. *J Toxicol Clin Toxicol* 1995; **33**: 295-310 [PMID: 7629896 DOI: 10.3109/15563659509028915]
- 65 **Fuentebella J**, Kerner JA. Refeeding syndrome. *Pediatr Clin North Am* 2009; **56**: 1201-1210 [PMID: 19931071 DOI: 10.1016/j.pcl.2009.06.006]
- 66 **Brown MJ**, Brown DC, Murphy MB. Hypokalemia from beta2-receptor stimulation by circulating epinephrine. *N Engl J Med* 1983; **309**: 1414-1419 [PMID: 6314140 DOI: 10.1056/NEJM198312083092303]
- 67 **Williams ME**, Gervino EV, Rosa RM, Landsberg L, Young JB, Silva P, Epstein FH. Catecholamine modulation of rapid potassium shifts during exercise. *N Engl J Med* 1985; **312**: 823-827 [PMID: 2858053 DOI: 10.1056/NEJM198503283121304]
- 68 **Young DB**. Quantitative analysis of aldosterone's role in potassium regulation. *Am J Physiol* 1988; **255**: F811-F822 [PMID: 3056039 DOI: 10.1152/ajprenal.1988.255.5.F811]
- 69 **Morales JM**, Andrés A, Dominguez-Gil B, Sierra MP, Arenas J, Delgado M, Casal MC, Rodicio L. Tubular function in patients with hypokalemia induced by sirolimus after renal transplantation. *Transplant Proc* 2003; **35**: 154S-156S [PMID: 12742489 DOI: 10.1016/s0041-1345(03)00224-0]
- 70 **Büchler M**, Caillard S, Barbier S, Thervet E, Toupance O, Mazouz H, Hurault de Ligny B, Le Meur Y, Thierry A, Villemain F, Heng AE, Moulin B, Morin MP, Noël C, Lebranchu Y; SPIESSER Group. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. *Am J Transplant* 2007; **7**: 2522-2531 [PMID: 17868057 DOI: 10.1111/j.1600-6143.2007.01976.x]
- 71 **Liu J**, Liu D, Li J, Zhu L, Zhang C, Lei K, Xu Q, You R. Efficacy and Safety of Everolimus for Maintenance Immunosuppression of Kidney Transplantation: A Meta-Analysis of Randomized Controlled Trials. *PLoS One* 2017; **12**: e0170246 [PMID: 28107397 DOI: 10.1371/journal.pone.0170246]
- 72 **Sundaram V**, Abraham G, Sundaram V, Mathew M, Bhaskar S, Ponnusamy J, Prabu S. Rapamycin-induced hypokalaemic nephropathy in a middle-aged hypertensive male. *Nephrol Dial Transplant* 2007; **22**: 1798 [PMID: 17347279 DOI: 10.1093/ndt/gfm081]
- 73 **Vlahovic G**, Meadows KL, Uronis HE, Morse MA, Blobe GC, Riedel RF, Zafar SY, Alvarez-Secord A, Gockerman J, Starodub AN, Ready NE, Anderson EL, Bendell JC, Hurwitz HI. A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. *Cancer Chemother Pharmacol* 2012; **70**: 95-102 [PMID: 22638798 DOI: 10.1007/s00280-012-1889-8]
- 74 **Shiina Y**, Kobayashi A, Yamamoto I, Koda N, Miyazawa K, Kawabe M, Sugano N, Urabe F, Miki J, Yamada H, Kimura T, Maruyama Y, Tanno Y, Ohkido I, Yamamoto H, Yokoo T. A Case of Hypokalemia Caused by Left Native Renal Artery Stenosis in a Kidney Transplant Recipient. *Nephron* 2023; **147** Suppl 1: 46-52 [PMID: 36940677 DOI: 10.1159/000530229]
- 75 **Fujimoto K**, Hisanaga S, Kuroda S, Kodama K, Sugiyama F, Kikuchi M, Kita T, Yamashita A, Nagai T, Kamimura T, Kaikita K, Imamura T, Fujimoto S. A case of primary aldosteronism with excessive secretion of renin that was unmasked by kidney transplantation. *CEN Case Rep* 2024; **13**: 1-8 [PMID: 37010722 DOI: 10.1007/s13730-023-00784-9]
- 76 **Medeiros H**, Lima PH, Junior VS, Souza DA, Pinheiro AM, Martins RR, A H Costa KM, Junior JHD, Medeiros PJ, Da Silva WA Sr. A Comparison Between Saline and Balanced Solutions in Kidney Transplants: A Randomized Clinical Trial. *Cureus* 2023; **15**: e49813 [PMID: 38164322 DOI: 10.7759/cureus.49813]
- 77 **O'Malley CMN**, Frumento RJ, Hardy MA, Benvenisty AI, Brentjens TE, Mercer JS, Bennett-Guerrero E. A randomized, double-blind comparison of lactated Ringer's solution and 0.9% NaCl during renal transplantation. *Anesth Analg* 2005; **100**: 1518-1524 [PMID: 15845718 DOI: 10.1213/01.ANE.0000150939.28904.81]
- 78 **Chen EH**, Hollander JE. When do patients need admission to a telemetry bed? *J Emerg Med* 2007; **33**: 53-60 [PMID: 17630076 DOI: 10.1016/j.jemermed.2007.01.017]
- 79 **Drew BJ**, Califf RM, Funk M, Kaufman ES, Krucoff MW, Laks MM, Macfarlane PW, Sommargren C, Swiryn S, Van Hare GF; American Heart Association; Councils on Cardiovascular Nursing, Clinical Cardiology, and Cardiovascular Disease in the Young. Practice standards for electrocardiographic monitoring in hospital settings: an American Heart Association scientific statement from the Councils on Cardiovascular Nursing, Clinical Cardiology, and Cardiovascular Disease in the Young: endorsed by the International Society of Computerized Electrocardiology and the American Association of Critical-Care Nurses. *Circulation* 2004; **110**: 2721-2746 [PMID: 15505110 DOI: 10.1161/01.CIR.0000145144.56673.59]
- 80 **Crop MJ**, Hoorn EJ, Lindemans J, Zietse R. Hypokalaemia and subsequent hyperkalaemia in hospitalized patients. *Nephrol Dial Transplant* 2007; **22**: 3471-3477 [PMID: 17848395 DOI: 10.1093/ndt/gfm471]
- 81 **Kim GH**, Han JS. Therapeutic approach to hypokalemia. *Nephron* 2002; **92** Suppl 1: 28-32 [PMID: 12401935 DOI: 10.1159/000065374]
- 82 **Blanchard A**, Bockenbauer D, Bolognani D, Calò LA, Cosyns E, Devuyt O, Ellison DH, Karet Frankl FE, Knoers NV, Konrad M, Lin SH, Vargas-Poussou R. Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney Int* 2017; **91**: 24-33 [PMID: 28003083 DOI: 10.1016/j.kint.2016.09.046]
- 83 **Huang CL**, Kuo E. Mechanism of hypokalemia in magnesium deficiency. *J Am Soc Nephrol* 2007; **18**: 2649-2652 [PMID: 17804670 DOI: 10.1681/ASN.2007070792]
- 84 **Kassirer JP**, Berkman PM, Lawrenz DR, Schwaartz WB. The critical role of chloride in correcting hypokalemic alkalosis in man. *Am J Med* 1965; **38**: 172-189 [PMID: 14256714 DOI: 10.1016/0002-9343(65)90172-5]
- 85 **Kopyt N**, Dalal F, Narins RG. Renal retention of potassium in fruit. *N Engl J Med* 1985; **313**: 582-583 [PMID: 4022094]
- 86 **Boslooper-Meulenbelt K**, Patijn O, Battjes-Fries MCE, Haisma H, Pot GK, Navis GJ. Barriers and Facilitators of Fruit and Vegetable Consumption in Renal Transplant Recipients, Family Members and Healthcare Professionals-A Focus Group Study. *Nutrients* 2019; **11** [PMID: 31614629 DOI: 10.3390/nu11102427]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: office@baishideng.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

